Cargando…
Targeted Therapy in Ovarian Cancer
Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherap...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814233/ https://www.ncbi.nlm.nih.gov/pubmed/20130818 http://dx.doi.org/10.1155/2010/740472 |
_version_ | 1782176988645031936 |
---|---|
author | Willmott, Lyndsay J. Fruehauf, John P. |
author_facet | Willmott, Lyndsay J. Fruehauf, John P. |
author_sort | Willmott, Lyndsay J. |
collection | PubMed |
description | Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, many patients will recur and ultimately die from their disease. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach. |
format | Text |
id | pubmed-2814233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28142332010-02-03 Targeted Therapy in Ovarian Cancer Willmott, Lyndsay J. Fruehauf, John P. J Oncol Review Article Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, many patients will recur and ultimately die from their disease. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach. Hindawi Publishing Corporation 2010 2010-01-14 /pmc/articles/PMC2814233/ /pubmed/20130818 http://dx.doi.org/10.1155/2010/740472 Text en Copyright © 2010 L. J. Willmott and J. P. Fruehauf. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Willmott, Lyndsay J. Fruehauf, John P. Targeted Therapy in Ovarian Cancer |
title | Targeted Therapy in Ovarian Cancer |
title_full | Targeted Therapy in Ovarian Cancer |
title_fullStr | Targeted Therapy in Ovarian Cancer |
title_full_unstemmed | Targeted Therapy in Ovarian Cancer |
title_short | Targeted Therapy in Ovarian Cancer |
title_sort | targeted therapy in ovarian cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814233/ https://www.ncbi.nlm.nih.gov/pubmed/20130818 http://dx.doi.org/10.1155/2010/740472 |
work_keys_str_mv | AT willmottlyndsayj targetedtherapyinovariancancer AT fruehaufjohnp targetedtherapyinovariancancer |